Many thanks for providing us with the opportunity to discuss our article entitled: Effects of silybum marianum on patients with chronic hepatitis C virus (HCV).1
We were glad to receive Dr. Alavian's comment entitled “Herbal medicine and liver disease, for any conclusion we need more studies”. HCV is a major cause of liver-related morbidity and mortality.2 Ribavirin plus interferon combination therapy is presently considered as an optimal treatment for patients with chronic hepatitis C, but the recommended treatment regimen is concerned with considerable expense, adverse effects and poor efficacy in some patients. Although the popularity of silymarin has been increased in people with liver diseases,3,4 a few evidences with controversial results exist regarding the effect of silymarin on chronic HCV infection.
Comment
According to critical opinions of the author that the result of HCV RNA seroconverted to negative was very amazing, it should be mentioned that our sample size was small (55 cases) and the 16.4% negative rate could be due to chance. We calculated 95% confidence interval (CI) which was from 7.8% to 28.8% that means the 16.4% point estimate may be due to random error.
All of the patients enrolled in our study were non cirrhotic and HIV negative. Their sonography reports were near normal. Because liver biopsy is an invasive method and many patients did not have any indication to do this, we assessed liver fibrosis including YKL-40 and Hyaluronic acid.5 The cause of death in one patient was not related to liver diseases or the prescribed herbal drug. Finally, we declare that our trial was open labeled (phase 2) and we recommend further researches especially blinded randomized placebo controlled clinical trials to clarify this issue.
Footnotes
Conflict of Interests Authors have no conflict of interests.
References
- 1.Kalantari H, Shahshahan Z, Hejazi M, Ghafghazi T, Sebghatolah V. Effects of silybum marianum on patients with chronic hepatitis C. J Res Med Sci. 2011;16(3):287–90. [PMC free article] [PubMed] [Google Scholar]
- 2.Kalantari H, Kazemi F, Minakari M. Efficacy of triple therapy with interferon alpha-2b, ribavirin and amantadine in the treatment of naïve patients with chronic hepatitis C. J Res Med Sci. 2007;12(4):178–85. [Google Scholar]
- 3.Luper S. A review of plants used in the treatment of liver disease: part 1. Altern Med Rev. 1998;3(6):410–21. [PubMed] [Google Scholar]
- 4.Mayer KE, Myers RP, Lee SS. Silymarin treatment of viral hepatitis: a systematic review. J Viral Hepat. 2005;12(6):559–67. doi: 10.1111/j.1365-2893.2005.00636.x. [DOI] [PubMed] [Google Scholar]
- 5.Gressner AM, Gao CF, Gressner OA. Non-invasive biomarkers for monitoring the fibrogenic process in liver: a short survey. World J Gastroenterol. 2009;15(20):2433–40. doi: 10.3748/wjg.15.2433. [DOI] [PMC free article] [PubMed] [Google Scholar]